Yahyapoor F, Sedaghat A, Bagherniya M, Pahlavani N, Khadem-Rezaiyan M, Safarian M, et al
The SURPASS-3 study was set up to investigate the efficacy and safety of tirzepatide versus a titration of the basal insulin degludec inadequately controlled by an oral therapy of T2D by metformin with or without an SGLT2 inhibitor comedication for 52 weeks (72)
Clinical evidence from extension trials suggests this reduces monthly costs by 2540% while maintaining 6075% of the weight loss achieved at higher doses, though individual response varies significantly
Mistake 04 Equating Research Volume with Evidence Quality BPC-157 has hundreds of published papers a volume that might suggest a robust evidence base
While both medications share the same active ingredient and mechanism of action, their differences in regulation, production standards, and accessibility can notably influence individual treatment success